NCT07280494

An Open-label, Clinical Study of CD7-targeted CAR-T Cells for the Treatment of Measurable Residual Disease of T-lymphoblastic Leukaemia/Lymphoma Post Allogeneic Stem Cell Transplantation

Study Summary

To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of T-lymphoblastic leukaemia/lymphoma with postive measurable residual disease positive post allogeneic stem cell transplantation

Want to learn more about this trial?

Request More Info

Interventions

CAR-T TherapyDRUG
autologous or donor-derived CD7-targeted CAR-T cells, single injection

Study Locations

FacilityCityStateCountry
Peking University People's HospitalBeijingChinaChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026